Skip to main content
OpenTrials
Completed

NCT Number: NCT00785460

Benfotiamine Prevents Vascular Dysfunction in Healthy Smokers

Benfotiamine pretreatment (3 days)at high dosage (1050 mg/day) prevents in healthy subjects smoking-induced vascular dysfunction assessed by ultrasound flow mediated dilatation of the brachial artery.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

20 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Heart and Diabetes Center

Bad Oeynhausen, North Rhine-Westphalia, 32545, Germany

About this study

Benfotiamine pretreatment (3 days)at high dosage (1050 mg/day) prevents in healthy subjects smoking-induced vascular dysfunction assessed by ultrasound flow mediated dilatation (FMD) of the brachial arteryand laboratory parameters (adhesion molecules).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • healthy habitual smokers

Exclusion criteria

  • any kind of chronic disease

Treatment and study plan

Benfotiamine

Drug

Primary outcomes

  1. Flow mediated dilatation

    Time frame: 3 days

Secondary outcomes

  1. Laboratory markers of endothelial function

    Time frame: 3 days

Sponsors and collaborators

Lead sponsor

Ruhr University of Bochum

Other

Registry information

Important dates

Study start
2008
Primary completion
2008
First posted
Nov 5, 2008
Registry last updated
Nov 5, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.